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lation between hematologic and organ response.
Results:Median age at auto-HCTwas 59 years (range, 41-74).
Median time from diagnosis to auto-HCT was 6.6 months
(2.2-121.9). Additional visceral organs involved were: heart 5
pts (9%), GI tract 3 pts (5%), peripheral nerves 1 pt (2%) and
liver 5 pts (9%). Median baseline 24-hour proteinuria was
5.055 grams (range, 0.17- 27.85 grams). All pts received
melphalan or melphalan-based combinations as their
preparative regimen.Median time to neutrophil engraftment
was 10 days (range, 7-15). Median follow up from auto-HCT
was 24.5 months (range, 0.4-132). Six pts died of non-relapse
causes with a non-relapse mortality (NRM) at both 100 days
and 1 year of 10.9%. Fifty pts were evaluable for a hemato-
logic response, while 5 patients were inevaluable due to
early death. Eight pts (16%) achieved complete remission
(CR), 10 (20%) achieved a very good partial remission (VGPR)
and 21 (42%) achieved a partial remission (PR), with an
overall response rate of 78%. Organ response was evaluated
at 6, 12, and 24 months, and was deﬁned as a 50% decrease
in total proteinuria over 24 hours without an increase of
25% of serum creatinine. Organ response was demon-
strated in 8 (17%) of 47 evaluable pts at 6 months, in 11 (29%)
of 38 evaluable pts at 12 months, and in 12 (44%) of 27
evaluable pts at 24 months, respectively. Organ responses at
last follow up were seen in 12 of 28 pts with > hematologic
PR and 0 of 11 pts with < hematologic PR (P ¼ .008). Two pts
who were hemodialysis-dependent pre auto-HCT remained
on dialysis after the auto-HCT. Median PFS and OS were 43.1
and 69.9 months, respectively. Kaplan-Meier estimates of 3-
year PFS and OS were 62% and 73%, respectively (Figure 1). At
the time of last follow-up, 37 pts (67%) were alive and in
remission.
Conclusions: High-dose melphalan and auto-HCT is associ-
ated with durable hematologic and organ response, and long
OS in patients with AL and renal involvement. Achievement
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Minneapolis, MNCD20 is a trans-membrane protein expressed onmature B
cells through all stages of their development. However, its
expression is down regulated at the point of differentiation
into plasma cells and expressed only in 16-22% of mature
plasma cells. CD20 expression on plasma cells has been
described with both favorable prognosis in association with
translocation t(11;14) and unfavorable prognosis in associa-
tion with plasma cell leukemia. The incidence of CD20
expression on plasma cells from patients with relapsed/
refractory multiple myeloma is not well stated in literature
and not routinely done in this patients' population. Addi-
tionally, it is not known if CD20 represents a primary aberrant
expression in newly diagnosed cases of multiple myeloma or
possibly represents a secondary genetic change at the time of
relapse related to hypothesized myeloma stem cells.
In order to study the above questions, we retrospectively
reviewed the medical records of 92 patients with symp-
tomatic MM who underwent ASCT between January 2008
and December 2011. As of July 2012, 38 patients have
relapsed. Bone marrow biopsy and ﬂow cytometry results
were available for 33 patients at time of diagnosis and
relapse. CD20 expression was positive on plasma cells by
ﬂow cytometry in 11 out of 33 patients (33%) at time of
relapse. Interestingly, CD20 expression at diagnosis was
negative in 4 out of these 11 patients. This up-regulation in
CD 20 expressionwas associatedwith clonal evolution in two
patients (deletion-17 and complex hypo-diploid cytogenetic,
respectively). Conﬁrmatory immune-histochemical staining
for CD20 was positive only in 2 of these 4 patients.
Conclusion: CD20 expression on plasma cells at time of
relapse/progression can occur in one third of patients with
multiple myeloma and may provide an additional thera-
peutic target. The cause of discrepancy between CD20
expression by ﬂow cytometry and immune-histochemical
staining is unclear and suggests that the two methods may
be complementary for a comprehensive evaluation of CD20
expression in multiple myeloma. CD20 up-regulation in
patients with relapsed/refractory myeloma who were
previously CD20 negative at diagnosis may represent
a secondary genetic event heralding a more aggressive
disease. Future prospective studies evaluating CD20 expres-
sion on plasma cells at different stages of disease progression
may optimize the timing for anti-CD20 therapy while har-
nessing the concept of colonogeneic myeloma stem cells.246
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Background: AL is characterized by the production of
monoclonal light chains which misfold, deposit in various
organs, including the heart, and cause early death. High dose
melphalan with SCT results in high hematologic response
(HR) rates and is standard treatment for eligible patients.
Achieving a CR to SCT results in extended EFS and OS. We
have studied novel agents as consolidation following
Table 1
Variables N (%)
Age, yrs (median, range) 33 (18 e 52)
Gender, Male 11 (58%)
Median # of prior therapies (range) 6 (2 e 8)
Prior autoHCT, yes 15 (79%)
Conditioning Intensity, Myeloablative 11 (58%)
Conditioning Regimen
Flu/Bu (AUC 5300, MAC) 9 (47%)
Flu/Bu (AUC 3500, RIC) 3 (16%)
Flu/Cy/TBI 200 1 ( 5%)
Flu/TBI 200 4 (21%)
Pento/Bu 2 (11%)
Disease status at HCT
Complete Remission 5 (26%)
Partial Remission 10 (53%)
Stable Disease 4 (21%)
Donor Type
Matched related 6 (32%)
Matched unrelated 6 (32%)
Mismatched unrelated 6 (32%)
Cord 1 ( 5%)
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outcomes. In this report we examine long-term outcomes of
pts who received initial therapy with RA-SCT followed by
consolidation for HR < CR.
Methods: We performed a retrospective study to assess the
HR rates, incidence of hematologic relapse and progression
(R/POD) and OS of AL pts enrolled at diagnosis on two
consecutive phase II trials using RA-SCT with consolidation
for HR < CR (NCT01527032 and NCT00458822). OS was
calculated from SCT to death or last follow up (f/u). Median
EFS and OS were estimated by the method of Kaplan Meier.
Cumulative incidence function was used to estimate the
incidence of R/POD and death.
Results: Between 2002 and 2011, 83 pts were enrolled and
underwent RA-SCTon these trials. Following RA-SCT, ptswith
HR < CR received consolidation with thalidomide and dexa-
methasone (TD) in the ﬁrst, and bortezomib and dexameth-
asone (BD) in the second trial. 36 pts had cardiac AL (43%) and
all had free light chain (FLC) measurements used to score HR
and R/POD using consensus criteria. The frequency of CR
following SCT was 24% and increased to 48% with post-SCT
consolidation. CR rates increased at 1 yr compared to 3 mos
post-SCT from 21% to 36% with TD and from 28% to 62% with
BD. With a median f/u of 5.1 yrs, the EFS is 4.5 yrs (95% CI: 2.6
to NR) and the OS of all pts has not been reached (Figure 1).16
pts died prior to R/POD and 26 pts have R/POD with
a cumulative incidence of R/POD of 8%, 18%, and 29% at 1, 2
and 3 yrs, respectively. 31% (8/26) of relapsed pts have not
required second-line therapy while among those who have,
78% (14/18) have responded including 44% (8/18) with CR.
Median OS following R/POD was 5 yrs (95% CI: 2.6-5.8).
Conclusions: Half of the AL pts on initial therapy trials
employing RA-SCT and consolidation for HR < CR achieved
CR with 36% of pts on the TD and 62% on the BD consolida-
tion trial in CR at 1 yr post-SCT. At 3 yrs post-SCT the
cumulative incidence of R/POD was 29% and 1/3 of relapsed
pts did not require therapy, likely due to the very sensitive
FLC assay that detects low level R/POD in the absence of
organ progression. Almost 80% of pts requiring second-line
therapy responded, over half with CR, and median OS after
relapse was 5 yrs. These results indicate that initial therapy
with RA-SCT and consolidation is effective for patients with
AL in the era of novel agents, and even relapsing pts have
excellent outcomes. With over 5 ys of f/u, median OS has not
been reached.
Figure 1. SEQ Figure \* ARABIC 1. EFS and OS following SCT and consolidation247
Increased Number of Prior Therapies and/or Use of
Mismatched Unrelated Donors Adversely Affect
Allogeneic Hematopoietic Cell Transplantation (alloHCT)
Outcomes in Relapsed/Refractory Hodgkin Lymphoma
(HL)
Asmita Mishra, Claudio Anasetti, Ernesto Ayala,
Hugo Fernandez, Teresa Field, Mohamed Kharfan-Dabaja,
Frederick Locke, Taiga Nishihori, Lia Perez, Marcie Tomblyn.
Blood and Marrow Transplantation, H. Lee Mofﬁtt Cancer
Center, Tampa, FL
Prognosis is poor for patients (pts) with refractory HL or
for those who relapse following autologous HCT (autoHCT).
Current salvage options aside from alloHCT remain palliative
but the role, timing and utility of alloHCT is not clear. We
report outcomes of 19 consecutive pts (Table 1) with
relapsed/refractory HL receiving alloHCT between 2005 and
2011 at Mofﬁtt Cancer Center. Data were obtained from the
BMT database and supplemented with chart review. Disease
responses are based on Cheson criteria (JCO 2007) and
chemotherapy sensitivity is deﬁned as PR or better at time of
alloHCT. Median follow-up for survivors is 44 months
(14e56). Treatment-relatedmortality (TRM) at day 100 and 1
yr are 27% (95% CI: 10-50) and 44% (95% CI: 23-67). The 1 yr
relapse rate was 32% (95% CI: 13e54). Grade 2 e 4 acute
GVHD by day 100 occurred in 82% (95% CI: 54e98); chronic
GVHD of any severity at 1 yr was 57% (95% CI: 25e86). Overall
survival (OS) and progression-free survival (PFS) at 1 yr are
47% (95% CI: 26-68) and 26% (95% CI: 10-48), respectively.
There were no differences in OS or PFS comparing myeloa-
blative (MAC) to reduced intensity (RIC) conditioning [OS:
MAC 55% (95% CI: 26e82) vs RIC 38% (95% CI: 10e71), P¼ .39;
PFS: MAC 27% (95% CI: 6e56) vs RIC 25% (95% CI: 3e58) P ¼
.78]. Relapse and TRM did not differ by conditioning inten-
sity. Disease status (CR vs PR/Stable disease) did not impact
OS, PFS, relapse or TRM. Pts receiving a mismatched unre-
lated donor (mMUD), including cord, had higher day 100
TRM compared to pts receiving a fully matched donor
[mMUD: 57% (95% CI: 22e88) vs matched: 9% (95%
CI:0e32)]. Three pts, including 1 receiving a mMUD, received
3 lines of chemotherapy including autoHCT preceding
allografting. In these pts, no TRM occurred compared to pts
with >3 lines of prior therapy having TRM of 53% (95% CI:
29e77). However, the improvement in 1 yr OS and PFS was
